{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T02:12:57Z","timestamp":1793412777237,"version":"4.5.0"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,3,2]],"date-time":"2023-03-02T00:00:00Z","timestamp":1677715200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,3,2]],"date-time":"2023-03-02T00:00:00Z","timestamp":1677715200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["211030\/Z\/18\/Z to SLNC as part of grant reference 203918\/Z\/16\/Z]"],"award-info":[{"award-number":["211030\/Z\/18\/Z to SLNC as part of grant reference 203918\/Z\/16\/Z]"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Rheumatol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Adalimumab in combination with other disease-modifying antirheumatic\u00a0drugs (DMARD) such as methotrexate has a proven efficacy in the management of paediatric non-infectious uveitis. However, many children experience significant intolerance to methotrexate while on this combination, leaving a dilemma for clinicians for choosing the subsequent therapeutic roadmap. Continuation of adalimumab monotherapy might be an alternative feasible option under such settings. This study aims to investigate the efficacy of adalimumab monotherapy in paediatric non-infectious uveitis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Children with non-infectious uveitis on adalimumab monotherapy (from August 2015 to June 2022) following intolerance to accompanying methotrexate or mycophenolate mofetil were included in this retrospective study. Data were collected at the initiation of adalimumab monotherapy and at three monthly intervals until the last visit. The primary outcome was to evaluate disease control on adalimumab monotherapy as determined by the proportion of patients who had less than a 2-step worsening in uveitis (as per SUN score) and no additional systemic immunosuppression during follow-up. Secondary outcome measures were visual outcome, complications and side-effect profile of adalimumab monotherapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Data was collected for 28 patients (56 eyes). The most common uveitis type and course were anterior and chronic uveitis respectively. Juvenile idiopathic arthritis-associated uveitis was the most common underlying diagnosis. During the study period, 23 (82.14%) of the study subjects met the primary outcome. On Kaplan\u2013Meier survival analysis 81.25% (95% CI; 60.6\u201391.7%) children maintained remission at 12\u00a0months on adalimumab monotherapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Continuation of adalimumab monotherapy is an effective therapeutic option for the treatment of non-infectious uveitis in children who are intolerant to the combination of adalimumab and methotrexate or mycophenolate mofetil.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12969-023-00794-y","type":"journal-article","created":{"date-parts":[[2023,3,2]],"date-time":"2023-03-02T13:02:48Z","timestamp":1677762168000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Outcome of adalimumab monotherapy in paediatric non-infectious uveitis"],"prefix":"10.1186","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2514-0638","authenticated-orcid":false,"given":"DA","family":"Al-Julandani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8004-0536","authenticated-orcid":false,"given":"NK","family":"Bagri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N","family":"Tsang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7385-6307","authenticated-orcid":false,"given":"S","family":"Clarke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5957-5429","authenticated-orcid":false,"given":"A","family":"Upadhyay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Guly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"AV","family":"Ramanan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,3,2]]},"reference":[{"issue":"1","key":"794_CR1","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1034\/j.1600-0420.2000.078001084.x","volume":"78","author":"T P\u00e4iv\u00f6nsalo-Hietanen","year":"2000","unstructured":"P\u00e4iv\u00f6nsalo-Hietanen T, Tuominen J, Saari KM. Uveitis in children: population-based study in Finland. Acta Ophthalmol Scand. 2000;78(1):84\u20138. https:\/\/doi.org\/10.1034\/j.1600-0420.2000.078001084.x.","journal-title":"Acta Ophthalmol Scand"},{"issue":"5","key":"794_CR2","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1016\/S0002-9394(02)02148-7","volume":"135","author":"C Edelsten","year":"2003","unstructured":"Edelsten C, Reddy MA, Stanford MR, Graham EM. Visual loss associated with pediatric uveitis in English primary and referral centers. Am J Ophthalmol. 2003;135(5):676\u201380. https:\/\/doi.org\/10.1016\/S0002-9394(02)02148-7.","journal-title":"Am J Ophthalmol"},{"issue":"2","key":"794_CR3","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1016\/j.survophthal.2021.06.006","volume":"67","author":"A Maleki","year":"2022","unstructured":"Maleki A, Anesi SD, Look-Why S, Manhapra A, Foster CS. Pediatric uveitis: A comprehensive review. Surv Ophthalmol Mar-Apr. 2022;67(2):510\u201329. https:\/\/doi.org\/10.1016\/j.survophthal.2021.06.006. (PMID: 34181974. Epub 2021 Jun 25).","journal-title":"Surv Ophthalmol Mar-Apr"},{"issue":"1","key":"794_CR4","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.semarthrit.2018.11.004","volume":"49","author":"A Heiligenhaus","year":"2019","unstructured":"Heiligenhaus A, Minden K, Tappeiner C, et al. Update of the evidence based, interdisciplinary guideline for anti-inflammatory treatment of uveitis associated with juvenile idiopathic arthritis. Semin Arthritis Rheum. 2019;49(1):43\u201355. https:\/\/doi.org\/10.1016\/j.semarthrit.2018.11.004.","journal-title":"Semin Arthritis Rheum"},{"issue":"5","key":"794_CR5","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1093\/rheumatology\/kes186","volume":"52","author":"G Simonini","year":"2012","unstructured":"Simonini G, Paudyal P, Jones GT, Cimaz R, Macfarlane GJ. Current evidence of methotrexate efficacy in childhood chronic uveitis: a systematic review and meta-analysis approach. Rheumatology. 2012;52(5):825\u201331.","journal-title":"Rheumatology"},{"issue":"5","key":"794_CR6","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1177\/112067210701700509","volume":"17","author":"A Heiligenhaus","year":"2007","unstructured":"Heiligenhaus A, Mingels A, Heinz C, Ganser G. Methotrexate for Uveitis Associated with Juvenile Idiopathic Arthritis: Value and Requirement for Additional Anti-Inflammatory Medication. Eur J Ophthalmol. 2007;17(5):743\u20138.","journal-title":"Eur J Ophthalmol"},{"issue":"3","key":"794_CR7","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/j.ajo.2005.03.057","volume":"140","author":"DA Jabs","year":"2005","unstructured":"Jabs DA, Nussenblatt RB, Rosenbaum JT, Standardization of Uveitis Nomenclature (SUN) Working Group. Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. Am J Ophthalmol. 2005;140(3):509\u201316 https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/16196117.","journal-title":"Am J Ophthalmol"},{"key":"794_CR8","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/s0161-6420(85)34001-0","volume":"92","author":"RB Nussenblatt","year":"1985","unstructured":"Nussenblatt RB, Palestine AG, Chan CC, Roberge F. Standardiza-tion of vitreal inflammatory activity in intermediate and posterior uveitis. Ophthalmol. 1985;92:467\u201371. https:\/\/doi.org\/10.1016\/s0161-6420(85)34001-0. (PMID:\u00a04000641).","journal-title":"Ophthalmol."},{"issue":"8","key":"794_CR9","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1136\/annrheumdis-2018-213131","volume":"77","author":"T Constantin","year":"2018","unstructured":"Constantin T, Foeldvari I, Anton J, de Boer J, Czitrom-Guillaume S, Edelsten C, Gepstein R, Heiligenhaus A, Pilkington CA, Simonini G, Uziel Y, Vastert SJ, Wulffraat NM, Haasnoot AM, Walscheid K, P\u00e1link\u00e1s A, Pattani R, Gy\u00f6rgyi Z, Kozma R, Boom V, Ponyi A, Ravelli A, Ramanan AV. Consensus-based recommendations for the management of uveitis associated with juvenile idiopathic arthritis: the SHARE initiative. Ann Rheum Dis. 2018;77(8):1107\u201317. https:\/\/doi.org\/10.1136\/annrheumdis-2018-213131. (PMID: 29592918 Epub 2018 Mar 28).","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"794_CR10","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1002\/acr.23871","volume":"71","author":"ST Angeles-Han","year":"2019","unstructured":"Angeles-Han ST, Ringold S, Beukelman T, Lovell D, Cuello CA, Becker ML, Colbert RA, Feldman BM, Holland GN, Ferguson PJ, Gewanter H, Guzman J, Horonjeff J, Nigrovic PA, Ombrello MJ, Passo MH, Stoll ML, Rabinovich CE, Sen HN, Schneider R, Halyabar O, Hays K, Shah AA, Sullivan N, Szymanski AM, Turgunbaev M, Turner A, Reston J. American College of Rheumatology\/Arthritis Foundation Guideline for the Screening, Monitoring, and Treatment of Juvenile Idiopathic Arthritis-Associated Uveitis. Arthritis Care Res (Hoboken). 2019;71(6):703\u201316. https:\/\/doi.org\/10.1002\/acr.23871. (Epub 2019 Apr 25PMID: 31021540).","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"17","key":"794_CR11","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1056\/NEJMoa1614160","volume":"376","author":"AV Ramanan","year":"2017","unstructured":"Ramanan AV, Dick AD, Jones AP, McKay A, Williamson PR, Compeyrot-Lacassagne S, et al. Adalimumab plus Methotrexate for Uveitis in Juvenile Idiopathic Arthritis. N Engl J Med. 2017;376(17):1637\u201346.","journal-title":"N Engl J Med"},{"key":"794_CR12","doi-asserted-by":"publisher","first-page":"2007","DOI":"10.1002\/art.30367","volume":"63","author":"M Bulatovi\u0107","year":"2011","unstructured":"Bulatovi\u0107 M, Heijstek MW, Verkaaik M, van Dijkhuizen EHP, Armbrust W, Hoppenreijs EPA, Kamphuis S, Kuis W, Egberts TCG, Sinnema G, Rademaker CMA, Wulffraat NM. High prevalence of methotrexate intolerance in juvenile idiopathic arthritis: Development and validation of a methotrexate intolerance severity score. Arthritis Rheum. 2011;63:2007\u201313. https:\/\/doi.org\/10.1002\/art.30367.","journal-title":"Arthritis Rheum"},{"issue":"1","key":"794_CR13","first-page":"148","volume":"34","author":"EH Pieter van Dijkhuizen","year":"2016","unstructured":"Pieter van Dijkhuizen EH, Pouw JN, Scheuern A, H\u00fcgle B, Hardt S, Ganser G, K\u00fcmmerle-Deschner JB, Horneff G, Holzinger D, \u0106alasan MB, Wulffraat NM. Methotrexate intolerance in oral and subcutaneous administration in patients with juvenile idiopathic arthritis: a cross-sectional, observational study. Clin Exp Rheumatol. 2016;34(1):148\u201354 (Epub 2016 Feb 2).","journal-title":"Clin Exp Rheumatol."},{"issue":"2019","key":"794_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2019\/1623847","volume":"10","author":"A Bitossi","year":"2019","unstructured":"Bitossi A, Bettiol A, Silvestri E, Di Scala G, Bacherini D, Lopalco G, et al. Adalimumab Accounts for Long-Term Control of Noninfectious Uveitis Also in the Absence of Concomitant DMARD Treatment: A Multicenter Retrospective Study. Mediators Inflamm. 2019;10(2019):1\u20138.","journal-title":"Mediators Inflamm"},{"issue":"11","key":"794_CR15","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1093\/ecco-jcc\/jjw152","volume":"10","author":"T Matsumoto","year":"2016","unstructured":"Matsumoto T, Motoya S, Watanabe K, Hisamatsu T, Nakase H, Yoshimura N, et al. Adalimumab Monotherapy and a Combination with Azathioprine for Crohn\u2019s Disease: A Prospective, Randomized Trial. J Crohn\u2019s Colitis. 2016;10(11):1259\u201366.","journal-title":"J Crohn\u2019s Colitis"},{"issue":"9","key":"794_CR16","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1016\/j.jid.2022.01.033","volume":"142","author":"G van der Kraaij","year":"2022","unstructured":"van der Kraaij G, Busard C, van den Reek J, Menting S, Musters A, Hutten B, de Rie M, Ouwerkerk W, van Bezooijen SJ, Prens E, Rispens T, de Vries A, de Jong E, de Kort W, Lambert J, van Doorn M, Spuls P. Adalimumab with Methotrexate vs Adalimumab Monotherapy in Psoriasis: First-Year Results of a Single-Blind Randomized Controlled Trial. J Invest Dermatol. 2022;142(9):2375\u201383. https:\/\/doi.org\/10.1016\/j.jid.2022.01.033. (Epub 2022 Mar 8).","journal-title":"J Invest Dermatol"},{"issue":"3","key":"794_CR17","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1136\/archdischild-2018-315060","volume":"104","author":"A Skrabl-Baumgartner","year":"2019","unstructured":"Skrabl-Baumgartner A, Seidel G, Langner-Wegscheider B, Schlagenhauf A, Jahnel J. Drug monitoring in long-term treatment with adalimumab for juvenile idiopathic arthritis-associated uveitis. Arch Dis Child. 2019;104(3):246\u201350. https:\/\/doi.org\/10.1136\/archdischild-2018-315060. (Epub 2018 Jul 19.PMID: 30026253).","journal-title":"Arch Dis Child"},{"key":"794_CR18","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.ajo.2022.03.017","volume":"240","author":"LEM Eurelings","year":"2022","unstructured":"Eurelings LEM, Missotten TOAR, van Velthoven MEJ, van Daele PLA, van Laar JAM, van Hagen PM, et al. Long-Term Follow-up of Patients with Uveitis Treated with Adalimumab: Response Rates and Reasons for Discontinuation of Therapy. Am J Ophthalmol. 2022;240:194\u2013204.","journal-title":"Am J Ophthalmol"}],"container-title":["Pediatric Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12969-023-00794-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12969-023-00794-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12969-023-00794-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,2]],"date-time":"2023-03-02T13:02:54Z","timestamp":1677762174000},"score":1,"resource":{"primary":{"URL":"https:\/\/ped-rheum.biomedcentral.com\/articles\/10.1186\/s12969-023-00794-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,2]]},"references-count":18,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["794"],"URL":"https:\/\/doi.org\/10.1186\/s12969-023-00794-y","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-2293755\/v1","asserted-by":"object"}]},"ISSN":["1546-0096"],"issn-type":[{"value":"1546-0096","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,2]]},"assertion":[{"value":"24 November 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 March 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was provided ethical waiver as per Institute norms.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable, as above.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"None.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"21"}}